Anti-epidermal growth factor receptor (EGFR) drug rechallenge could be of therapeutic value in a subgroup of refractory metastatic colorectal cancer (mCRC).
Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial.
Annals of Oncology | | D. Ciardiello, G. Martini, L.Boscolo Bielo, F. Pietrantonio, A. Raimondi, P. Manca, S. Pisconti, C. Nisi, G. Tortora, L. Salvatore, A. Sartore-Bianchi, S. Siena, L. Blasi, E. Ongaro, A. Zaniboni, C. Pinto, L. Antonuzzo, A. Avallone, N. Normanno, G. Santabarbara, M.G. Zampino, R. Berardi, A. Cogoni, C. Lotesoriere, T.P. Latiano, E. Maiello, N. Fazio, G. Curigliano, R. Bordonaro, T. Troiani, F. De Vita, E. Martinelli, F. Ciardiello, S. Napolitano, CAVE-2 GOIM study group
Topics: lung-cancer, colorectal-cancer, skin-cancer, blood-cancer, clinical-trials